Global bionetworks and challenges in regulating autologous adult stem cells

Tamra Lysaght, Ian Kerridge, Douglas Sipp, Gerard Porter, Benjamin J. Capps

Résultat de recherche: Comment/debateexamen par les pairs

3 Citations (Scopus)
Langue d'origineEnglish
Pages (de-à)941-943
Nombre de pages3
JournalAmerican Journal of Medicine
Volume126
Numéro de publication11
DOI
Statut de publicationPublished - nov. 1 2013
Publié à l'externeOui

Note bibliographique

Funding Information:
The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as Emergent Forms of Life and Practice” project, funded by the Ministry of Education, Singapore , and the Humanities and Social Sciences Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore.

Funding Information:
The concept of bionetworks has been described in a study 3 funded by the Ethics & Social Science Research Council in the United Kingdom. This study traces the relationships among physicians, science entrepreneurs, researchers, patients, and healthcare providers who are offering adult stem cells outside clinical trials as experimental therapies across Asia. According to the authors, bionetworks operate mostly, although not exclusively, within the private healthcare sector and work to exploit differences and similarities in the provision of healthcare, standards of evidence, and regulatory infrastructure across geographic contexts. 4 They also may work to shape healthcare policies and regulations across international borders.

ASJC Scopus Subject Areas

  • General Medicine

Citer